

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Abemaciclib in combination with fulvestrant for treating advanced hormone receptor-positive, HER2-negative breast cancer (CDF review of TA579)

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Eli Lilly (abemaciclib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Breast Cancer Care • Breast Cancer Now • Breast Cancer UK • Cancer Black Care • Cancer Equality • Haven • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Wellbeing of Women <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Breast Surgery • Association of Cancer Physicians • Association of Surgeons of Great Britain & Ireland • British Association of Surgical Oncology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • Cancer Research UK 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (exemestane) • Amneal Pharma Europe Limited (exemestane) • Consilient Health (exemestane) • Glenmark (exemestane) • Mylan (exemestane) • Novartis Pharmaceuticals (everolimus)

National Institute for Health and Care Excellence

Final stakeholder list for the appraisal of abemaciclib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer (CDF review of TA579)

Issue date: August 2020

© National Institute for Health and Care Excellence 2018. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Breast Cancer Group • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Newbury and District CCG • NHS Sheffield CCG • Welsh Government 	<ul style="list-style-type: none"> • Pfizer (exemestane) • Teva UK (exemestane) • Zentiva (exemestane) <p><u>Other relevant companies</u></p> <ul style="list-style-type: none"> • AstraZeneca (fulvestrant) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Against Breast Cancer • Breast Cancer Hope • Breast Cancer Research Trust • Cochrane Breast Cancer Group • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Pro-Cancer Research Fund <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.